quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:43:27·43d
SECFiling
Evofem Biosciences Inc. logo

SEC Form 10-K filed by Evofem Biosciences Inc.

EVFM· Evofem Biosciences Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • EVFM
    Evofem Biosciences Inc.
    Health Care

Recent analyst ratings

  • Mar 4UpdateMorgan Stanley$0.53
  • Nov 16UpdateHC Wainwright & Co.$2.00
  • Oct 21UpdateHC Wainwright & Co.$2.50
  • Oct 14UpdateMorgan Stanley$0.80
  • Aug 12UpdateMorgan Stanley$1.00

Related

  • SEC7d
    Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  • SEC35d
    Evofem Biosciences Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
  • SEC43d
    SEC Form 8-K filed by Evofem Biosciences Inc.
  • SEC101d
    Evofem Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • SEC148d
    Evofem Biosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
  • PR154d
    Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
  • SEC161d
    Evofem Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR161d
    Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022